From: Ionizable drug delivery systems for efficient and selective gene therapy
Ionizable nanomaterials | Nucleic acid | Application | Product | Clinical Phase |
---|---|---|---|---|
SM-102 | mRNA | COVID-19 vaccine | Spikevax® | Approved in 2021 |
Acuitas ALC-0315 | mRNA | COVID-19 vaccine | Comirnaty® | Approved in 2021 |
MC3 | siRNA | ATTR | Onpattro® | Approved in 2018 |
ALC-0315 | mRNA | COVID-19 vaccine | CVnCoV | III |
A9 | mRNA | COVID-19 vaccine | LNP-nCo VsaRNA | I |
CL1 | mRNA | COVID-19 vaccine | ChulaCov19 | I |
ATX | mRNA | COVID-19 vaccine | LUNAR-COV19 (ARCT-021) | III |
- | mRNA | COVID-19 vaccine | ARCoV | III |
COVID-19 vaccine | PTX-COVID19B | II | ||
ATX | mRNA | Ornithine transcarbamylase deficiency | LUNAR-OTC (ARCT-810) | II |
Cystic fibrosis | LUNAR-CF (ARCT-032) | Preclinical | ||
Influenza | LUNAR-FLU | Preclinical | ||
Hemophilia B | LUNAR® | Preclinical | ||
LPO1 | sgRNA | ATTR | NTLA-2001 | I |